Detailed report on Melanoma Treatment Market Trends scrutinized in new research

WILMINGTON, Del. - July 21, 2016 - PRLog -- The global treatment market for melanoma will expand more than fourfold in value from $1.34 billion in 2013 to reach an estimated $5.64 billion by 2023, representing a robust Compound Annual Growth Rate (CAGR) of 15.5%, according to MarketIntelReports

"Melanoma Global Clinical Trials Review, H1, 2016" provides an overview of Melanoma clinical trials scenario. This report provides top line data relating to the clinical trials on Melanoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

MarketIntelReports latest report states that this impressive growth, which will occur across the eight major markets (8MM) of the US, France, Germany, Italy, Spain, UK, Japan, and Australia, will be driven primarily by increasing sales of Bristol-Myers Squibb's blockbuster immunotherapy Yervoy.

"While Yervoy's sales will be negatively impacted by the first-line uptake of PD-1-targeting monoclonal antibodies (mAbs) Keytruda and Opdivo from 2015 to 2017, the approval of the Yervoy/Opdivo combination will recover the former's market position in the second half of the forecast period.

"Furthermore, Yervoy's label expansion into the lucrative adjuvant setting will further enhance its sales from 2019 onwards."

MarketIntelReports estimates sales of $889 million for Yervoy in the 8MM in 2013, and forecasts this to rise at a CAGR of 8.2% to $1.96 billion by 2023.

Some of the prominent players of market:

Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Merck & Co., Inc. Novartis AG AstraZeneca Plc Pfizer Inc. Ludwig Institute For Cancer Research Ltd Eisai Co., Ltd. Amgen Inc. and Others

The BRAF/MEK inhibitor combinations, in particular Novartis' Tafinlar/Mekinist and Roche/Exelixis' Zelboraf/cobimetinib, will replace standard BRAF inhibitor monotherapy of Zelboraf or Tafinlar. In addition, Keytruda and Opdivo will garner rapid growth in both BRAF mutated and wild-type settings.

"These novel agents and combinations will experience large uptake globally, thanks to their improved overall response rate and overall survival, along with their manageable side effect profiles. Notably, the combination treatments will fetch a higher premium price than monotherapies, which, on top of raising company sales, will also result in greater pushback from payers."

Browse Melanoma Global Clinical Trials Review, H1, 2016 Research Report
http://www.marketintelreports.com/report/gdhc3214ctidb/melanoma-global-clinical-trials-review-h1-2016

Request for Sample Brochure of Report @ http://www.marketintelreports.com/pdfdownload.php?id=gdhc3214ctidb

MarketIntelReports expects these new, more efficacious entrants to replace generic chemotherapy-only regimens in the first- and second-line settings, therefore driving the growth of the overall melanoma market and extending the lines of treatment available for patients.

"The launch of these improved agents will ensure that many patients receive one to two lines of treatment with branded premium-priced drugs by 2023 and beyond."

Key Benefits of Report:

-          Assists in formulating key business strategies with regards to investment

-          Helps in identifying prominent locations for conducting clinical trials which saves time and cost

-          Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

-          Supports understanding of trials count and enrollment trends by country in global therapeutics market

-          Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

-          Facilitates clinical trial assessment of the indication on a global, regional and country level

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Our Clinical Trial Reports are generated using our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Order Melanoma Global Clinical Trials Review, H1, 2016 @ http://www.marketintelreports.com/purchase.php?id=gdhc3214ctidb

About us:

MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.

A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.

Contact us:
Sales Manager
Mayur S.
2711 Centerville Road, Suite 400, Wilmington,Delaware,19808
United States
www.marketintelreports.com
sales@marketintelreports.com
Telephone: 1-302-261-5343 (http://www.marketintelreports.com)